| Methods |
4‐week single‐blind placebo run‐in; inclusion criteria= sitting DBP 95‐114 mm Hg at last 2 visits of run‐in; 12‐week double‐blind treatment |
| Participants |
Lisinopril 10 mg: n=26(18 males,8 females); mean age=70.5 years; baseline sitting SBP=163.8(13.0) mm Hg, DBP=104.9(5.0) mm Hg, HR=62.5 bpm;
Placebo: n=27(15 males,12 females); mean age=73.4 years; baseline sitting SBP=167.9(14.8) mm Hg, DBP=105.5(5.4) mm Hg, HR=61.9 bpm |
| Interventions |
Lisinopril 10 mg once daily;
Placebo;
taken between 8 AM and 10 AM |
| Outcomes |
Mean change from baseline in trough sitting SBP/DBP using mercury sphygmomanometer;
WDAE |
| Notes |
BP change and SD of change reported, endpoint BP and SD reported; SD of change values are too low; imputed endpoint SBP SD for SBP SD of change; imputed overall trial mean DBP SD of change; SBP data from Table 2, p. 745; DBP data from Table 3, p. 746; Jadad score=3; funding source= not reported |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
